Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.

The Italian Society for Infectious and Tropical Diseases (SIMIT) in collaboration with the Technical Health Committee (Sections L and M) of the Italian Ministry of Health have supported the renewal of the recommendations for the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. This publication summarizes the latest updates to the 2017 version of the Italian Guidelines for the management of HIV-1 infected patients and the use of antiretroviral drugs. New recommendations were released framing the clinical questions the use of antiretrovirals according to the Patient Intervention Comparator Outcome (PICO) methodology and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Diagnostic tools for immunological and virological monitoring, when to start, what to start, optimization and therapeutic failure were updated in order to include the recommendation obtained with these newly developed methods. For a complete review of clinical and therapeutic relevant topics we refer the reader to the extended version of the Guidelines.

[1]  J. Sutinen,et al.  Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. , 2019, AIDS patient care and STDs.

[2]  Alimuddin Zumla,et al.  Isoniazid preventive therapy for children in sub-Saharan Africa. , 2019, The Lancet. Respiratory medicine.

[3]  A. d’Arminio Monforte,et al.  Brief Report: Drop in CD4+ Counts Below 200 Cells/&mgr;L After Reaching (or Starting From) Values Higher than 350 Cells/&mgr;L in HIV-Infected Patients With Virological Suppression , 2017, Journal of acquired immune deficiency syndromes.

[4]  R. Siliciano,et al.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study , 2017, PLoS medicine.

[5]  C. Katlama,et al.  Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. , 2017, The lancet. HIV.

[6]  L. Cuzin,et al.  Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization , 2017, Journal of acquired immune deficiency syndromes.

[7]  O. Turriziani,et al.  Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. , 2017, Journal of global antimicrobial resistance.

[8]  A. Mocroft,et al.  Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. , 2017, International journal of antimicrobial agents.

[9]  K. White,et al.  Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128) , 2017, HIV clinical trials.

[10]  N. Rocha-Pereira,et al.  Routine CD4 monitoring in HIV patients with viral suppression: Is it really necessary? A Portuguese cohort. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[11]  P. Harrigan,et al.  Emergent drug resistance with integrase strand transfer inhibitor-based regimens , 2017, AIDS.

[12]  Richard D Moore,et al.  Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. , 2017, The lancet. HIV.

[13]  A. LaMarca,et al.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. , 2017, The lancet. HIV.

[14]  D. Cooper,et al.  Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial , 2017, The lancet. HIV.

[15]  D. Niewoehner,et al.  Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. , 2016, The Lancet. Respiratory medicine.

[16]  R. Bedimo,et al.  Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection , 2016, HIV clinical trials.

[17]  A. d’Arminio Monforte,et al.  Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice , 2016, PloS one.

[18]  K. White,et al.  Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. , 2016, The lancet. HIV.

[19]  V. Calvez,et al.  Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. , 2016, The Journal of antimicrobial chemotherapy.

[20]  A. Samri,et al.  Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). , 2016, The Journal of antimicrobial chemotherapy.

[21]  J. Ananworanich,et al.  HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART , 2016, EBioMedicine.

[22]  Josefa D. López,et al.  Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure , 2016, BMC Infectious Diseases.

[23]  K. Tashima,et al.  Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results , 2016, Journal of acquired immune deficiency syndromes.

[24]  G. d’Ettorre,et al.  Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First‐Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen , 2016, HIV medicine.

[25]  T. F. Rinke de Wit,et al.  HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing , 2015, PloS one.

[26]  J. Currier,et al.  A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness , 2015, AIDS.

[27]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[28]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[29]  M. Saag,et al.  Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study , 2015, Journal of Acquired Immune Deficiency Syndromes.

[30]  M. Poljak,et al.  Primary resistance to integrase strand-transfer inhibitors in Europe. , 2015, The Journal of antimicrobial chemotherapy.

[31]  F. Antunes,et al.  Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results , 2015, Journal of acquired immune deficiency syndromes.

[32]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[33]  F. Ceccherini‐Silberstein,et al.  HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. , 2015, The Journal of antimicrobial chemotherapy.

[34]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. , 2015, The lancet. HIV.

[35]  M. Johnson,et al.  Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial , 2015, The Patient - Patient-Centered Outcomes Research.

[36]  K. Tashima,et al.  Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial , 2014, AIDS Research and Therapy.

[37]  David W. Haas,et al.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. , 2014, Annals of internal medicine.

[38]  G. Kronborg,et al.  Effectiveness of Antiretroviral Therapy in Individuals Who for Economic Reasons Were Switched From a Once-Daily Single-Tablet Regimen to a Triple-Tablet Regimen , 2014, Journal of acquired immune deficiency syndromes.

[39]  D. Boulware,et al.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. , 2014, The New England journal of medicine.

[40]  K. White,et al.  Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults , 2014, AIDS.

[41]  F. Maggiolo,et al.  Single-Tablet Regimens in HIV Therapy , 2014, Infectious Diseases and Therapy.

[42]  G. d’Ettorre,et al.  Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) , 2014, Scandinavian journal of infectious diseases.

[43]  C. Orkin,et al.  Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials , 2014, HIV medicine.

[44]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[45]  R. Walensky,et al.  Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. , 2013, JAMA internal medicine.

[46]  A. Antinori,et al.  Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines , 2013, ClinicoEconomics and outcomes research : CEOR.

[47]  H. Stellbrink,et al.  96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study , 2013, Antiviral therapy.

[48]  M. Bloch,et al.  Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies , 2013, HIV clinical trials.

[49]  A. Labriola,et al.  Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression? , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  H. Crauwels,et al.  Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. , 2013, AIDS reviews.

[51]  H. Stellbrink,et al.  Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials , 2013, AIDS.

[52]  G. Colombo,et al.  Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen , 2013, ClinicoEconomics and outcomes research : CEOR.

[53]  D. Podzamczer,et al.  The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy. , 2012, AIDS reviews.

[54]  G. Oster,et al.  Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens , 2012, Expert opinion on pharmacotherapy.

[55]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.

[56]  S. Rowland-Jones,et al.  Clinical predictors cannot replace biological predictors in HIV-2 infection in a community setting in West Africa , 2012, International Journal of Infectious Diseases.

[57]  B. Clotet,et al.  Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials , 2012, Journal of acquired immune deficiency syndromes.

[58]  D. Katzenstein,et al.  Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.

[59]  B. Clotet,et al.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial , 2011, The Lancet.

[60]  J. Farrar,et al.  Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  D. Katzenstein,et al.  Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.

[62]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[63]  C. Hurt.  Article Commentary: Transmitted Resistance to HIV Integrase Strand-Transfer Inhibitors: Right on Schedule , 2011, Antiviral therapy.

[64]  D. Podzamczer,et al.  Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study , 2010, Journal of acquired immune deficiency syndromes.

[65]  D. Costagliola,et al.  Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. , 2010, Archives of internal medicine.

[66]  Lynne Peeples,et al.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.

[67]  D. Fine,et al.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.

[68]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[69]  Shabbar Jaffar,et al.  Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study , 2009, Journal of acquired immune deficiency syndromes.

[70]  Giulia Marchetti,et al.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  陳怡然.  嵌入酶抑制劑(integrase inhibitor)的新進展 , 2008 .

[72]  N. Udupa,et al.  Fixed dose combinations: Rational or irrational? , 2008 .

[73]  Bruno Ledergerber,et al.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.

[74]  A. Telenti,et al.  CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. , 2003, Archives of internal medicine.

[75]  R. Root.  Clinical infectious diseases: a practical approach. , 1999 .

[76]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[77]  A. d’Arminio Monforte,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. , 2017, The new microbiologica.

[78]  Ann M. Dennis,et al.  Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016. , 2017, AIDS.

[79]  P. Sax,et al.  Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment Week 144 Results , 2017, Journal of acquired immune deficiency syndromes.

[80]  S. Walmsley,et al.  Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. , 2017, The lancet. HIV.

[81]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. , 2011, The new microbiologica.

[82]  A. Telenti,et al.  CD 4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years The Swiss HIV Cohort Study , 2003 .

[83]  M. Wainberg,et al.  HIV-1 Drug Resistance , 2002 .

[84]  H. V. Smith.  TUBERCULOUS MENINGITIS. , 1964, International journal of neurology.